Last reviewed · How we verify

Tabrecta (CAPMATINIB)

Novartis Pharm · FDA-approved approved Small molecule Quality 66/100

Tabrecta works by blocking the hepatocyte growth factor receptor, a protein that helps cancer cells grow and spread.

Capmatinib (Tabrecta), marketed by Novartis, is a targeted therapy for metastatic NSCLC with MET exon 14 skipping, positioning it in a niche but critical segment of the oncology market. Its key strength lies in its mechanism of action, which specifically blocks the hepatocyte growth factor receptor, offering a precise treatment option for this patient population. The primary risk to Capmatinib's market position is the upcoming key patent expiry in 2028, which could lead to increased competition from generics and biosimilars.

At a glance

Generic nameCAPMATINIB
SponsorNovartis Pharm
Drug classKinase Inhibitor
TargetHepatocyte growth factor receptor
ModalitySmall molecule
Therapeutic areaOncology
PhaseFDA-approved
First approval2020
Annual revenue200

Mechanism of action

Capmatinib is kinase inhibitor that targets MET, including the mutant variant produced by exon 14 skipping. MET exon 14 skipping results in protein with missing regulatory domain that reduces its negative regulation leading to increased downstream MET signaling. Capmatinib inhibited cancer cell growth driven by mutant MET variant lacking exon 14 at clinically achievable concentrations and demonstrated anti-tumor activity in murine tumor xenograft models derived from human lung tumors with either mutation leading to MET exon 14 skipping or MET amplification. Capmatinib inhibited the phosphorylation of MET triggered by binding of hepatocyte growth factor or by MET amplification, as well as MET-mediated phosphorylation of downstream signaling proteins and proliferation and survival of MET-dependent cancer cells.

Approved indications

Common side effects

Key clinical trials

Patents

PatentExpiryType

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results
FDA Orange BookPatents + exclusivity
SEC EDGARRevenue + earnings

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: